Thursday 21 November 2024

The Pharma Letter Podcast — Episode 27 — How to develop cancer drugs faster, with Ellipses Pharma

Biotechnology
Simon Wentworth
23 January 2024
episode-27-big

More on this story...

Pharmaceutical
Growing J&J sales tempered by rising costs
23 January 2024
Pharmaceutical
Doubling down on deep customer insights to inform value demonstration
5 February 2024
Pharmaceutical
Positive pharma report finds increased funding, productivity and product launches in 2023
26 February 2024
Pharmaceutical
BRIEF—Trends shaping healthcare marketplace analyzed in report
2 February 2024


Companies featured in this story

More ones to watch >


Today's issue

EC approval for Pfizer’s Hympavzi
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Pharmaceutical
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Biosimilars
Xbrane and Intas to jointly develop Opdivo biosimilar
20 November 2024
Pharmaceutical
Chris Boshoff takes on new role at Pfizer
20 November 2024
Biotechnology
Two Neds better than one in Jupiter’s world of moons
20 November 2024
Pharmaceutical
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Biotechnology

EC approval for Pfizer’s Hympavzi
20 November 2024
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Two Neds better than one in Jupiter’s world of moons
20 November 2024
JAK inhibitors redefining atopic dermatitis treatment
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze